1
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 – MBC
Condition(s):Invasive Breast Cancer; Metastatic Breast Cancer; HR-Positive Breast Cancer; HER2-negative Breast CancerLast Updated:June 28, 2022Recruiting
TRODELVY: 21 Clinical Trials, Page 1 of 3
Hide Studies Not Open or Pending
2
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBC
Condition(s):Breast Cancer; Triple Negative Breast Cancer; PD-L1 NegativeLast Updated:March 16, 2022Recruiting
3
Trilaciclib in Patients Receiving Sacituzumab Govitecan-hziy for Triple Negative Breast Cancer
Condition(s):Triple Negative Breast CancerLast Updated:June 9, 2022Recruiting
4
Sacituzumab Govitecan Plus EV in Metastatic UC
Condition(s):Urothelial Cancer; Metastatic Urothelial Carcinoma; Metastatic Urothelial Carcinoma of the Renal Pelvis and Ureter; Bladder CancerLast Updated:June 1, 2022Recruiting
5
Alpelisib And Sacituzumab Govitecan For Treatment Of Breast Cancer
Condition(s):Breast CancerLast Updated:April 12, 2022Recruiting
6
Atezolizumab + Sacituzumab Govitecan to Prevent Recurrence in TNBC (ASPRIA)
Condition(s):Breast Cancer; Triple Negative Breast Cancer; Residual Cancer; Circulating Tumor DNALast Updated:May 27, 2022Recruiting
7
Study of Sacituzumab Govitecan-hziy (SG) in Japanese Participants With Advanced Solid Tumors or Triple-negative Breast Cancer
Condition(s):Advanced Solid Tumors or Triple-negative Breast CancerLast Updated:June 30, 2022Recruiting
8
Rollover Study in Participants With Metastatic Solid Tumors Benefiting From Therapy With Sacituzumab Govitecan-hziy
Condition(s):Metastatic Solid TumorLast Updated:July 13, 2022Enrolling by invitation
9
Combination of Ipi/Nivo Plus Sacituzumab Govitecan in Metastatic Cisplatin Ineligible Urothelial Carcinoma Patients
Condition(s):Metastatic Urothelial CarcinomaLast Updated:August 5, 2022Recruiting
10
Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician’s Choice in Patients With Previously Untreated Metastatic Triple-Negative Breast Cancer
Condition(s):Triple Negative Breast Cancer; PD-L1 NegativeLast Updated:May 19, 2022Recruiting